Trial: 202104073

A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti- tumor Activity of ARX517 in Subjects with Advanced Solid Tumors Resistant or Refractory to Standard Therapies



Principal Investigator

Pachynski, Russell

Disease Site

Breast; Cervix; Colon; Corpus Uteri; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Male Genital; Ovary; Pancreas; Prostate; Rectum; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: